News

May 22, 2019

Japanese Researchers Use Hyperion Imaging Tool to Advance Treatment Discovery for Colorectal Cancer

News

The National Cancer Center (NCC) in Japan is advancing its research into novel immunotherapies for colorectal cancer by using the Hyperion Imaging System, a powerful tool that enables simultaneous ... Read more

May 17, 2019

First Patients Dosed in iTeos’ Experimental A2A Receptor Antagonist Trial for Solid Tumors

News

iTeos Therapeutics’ Phase 1/1b clinical trial testing its experimental A2A receptor antagonist, EOS100850, has dosed the first group of patients with advanced solid tumors, the company announced. “I am ... Read more

May 14, 2019

$4.6M CIRM Grant to Fund Phase 1 Trial of New Immunotherapy for Advanced Sarcoma, Difficult-to-Treat Cancers

News

The California Institute for Regenerative Medicine (CIRM) has awarded a $4.6 million grant to researchers at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research ... Read more

May 8, 2019

Gritstone to Move Slate Immunotherapy into Clinical Trial Sooner than Anticipated

News

Gritstone Oncology is advancing its investigational immunotherapy Slate into Phase 1 clinical studies sooner than planned, and expects patient enrollment to start as early as mid-2019, the company announced. ... Read more

May 7, 2019May 7, 2019

Combining Radiation with Immune Checkpoint Inhibitors Improved Outcomes in Glioblastoma Mice

News

Combining radiation therapy with immune checkpoint inhibitors induces an immune response to both irradiated and non-irradiated glioblastoma, a study in mice found, suggesting that a combination of these approaches ... Read more

May 3, 2019

Sound Biologics to Launch Phase 1 Trial Assessing Its Candidate Immunotherapy for Solid Tumor Patients

News

Sound Biologics is launching a Phase 1 trial to test its candidate immunotherapy PSB205 in relapsed or refractory solid tumor patients, after the U.S. Food and Drug Administration cleared ... Read more

April 30, 2019

Keytruda-Inlyta Combo Approved by FDA for Untreated Advanced Kidney Cancer

News

The U.S. Food and Drug Administration (FDA) has approved a combination of Keytruda (pembrolizumab) plus Inlyta (axitinib) for the initial treatment of patients with advanced renal cell carcinoma, the ... Read more

April 26, 2019April 29, 2019

PureTech Presents Data About Two Promising Anti-cancer Therapies

News

PureTech Health is developing two promising candidate therapies that target key immunosuppressive mechanisms in cancer and may be used against cancers that fail to respond to existing immunotherapy approaches. The ... Read more

April 24, 2019

Aprea’s APR-246 Stabilizes Key Tumor Suppressor Protein and Boosts Immune Responses in Mouse Study

News

Aprea Therapeutics‘ APR-246 stabilizes the tumor suppressor protein p53, boosting responses to checkpoint blockade immunotherapies in mouse models of melanoma and colorectal cancer, a study says. Findings were announced ... Read more

April 23, 2019

Melanomas with NF-kB Activation Are Easier to Target with Immune Checkpoint Inhibitors, Study Says

News

Melanomas with a high number of genetic mutations that lead to over-activation of the nuclear factor-κB (NF-κB) signaling cascade — a family of gene expression regulators — are about ... Read more

Pin It on Pinterest